Suppr超能文献

分化型T1-2 N0甲状腺癌的半甲状腺切除术与全甲状腺切除术:系统评价和荟萃分析

Hemithyroidectomy versus total thyroidectomy for well differentiated T1-2 N0 thyroid cancer: systematic review and meta-analysis.

作者信息

Rodriguez Schaap P M, Botti M, Otten R H J, Dreijerink K M A, Nieveen van Dijkum E J M, Bonjer H J, Engelsman A F, Dickhoff C

机构信息

Department of Surgery, Amsterdam, the Netherlands.

Department of General Surgery, University of Pavia, IRCSS Fondazione Policlinico San Matteo, Pavia, Italy.

出版信息

BJS Open. 2020 Oct 6;4(6):987-94. doi: 10.1002/bjs5.50359.

Abstract

BACKGROUND

Evidence for limiting the extent of surgery in patients with low-risk thyroid cancer is lacking.

METHODS

A systematic search was performed according to the PRISMA and MOOSE guidelines to assess the effect of total thyroidectomy (TT) with or without radioactive iodine (RAI) treatment versus hemithyroidectomy (HT) on recurrence and overall mortality in patients with differentiated (papillary or follicular) T1-2 N0 thyroid cancer. PubMed, Embase and Cochrane databases were searched, and two authors independently assessed the articles.

RESULTS

A total of ten eligible articles were identified. All were observational cohort series, representing a total of 23 134 patients, of which 17 699 were available for meta-analysis. Six studies included patients who had TT followed by RAI treatment. The pooled recurrence rate after TT ± RAI and HT was 2·3 and 2·8 per cent respectively (odds ratio (OR) 1·12, 95 per cent c.i. 0·82 to 1·53; P = 0·48). The pooled 20-year overall survival rate after TT ± RAI was 96·8 per cent, compared with 97·4 per cent for HT (OR 1·30, 0·71 to 2·37; P = 0·40). Overall, higher complication rates were found in the TT ± RAI group.

CONCLUSION

Recurrence rates after HT for treatment of well differentiated T1-2 N0 thyroid cancer were similar to those after TT ± RAI, with a lower incidence of treatment-related complications.

摘要

背景

缺乏限制低风险甲状腺癌患者手术范围的证据。

方法

根据PRISMA和MOOSE指南进行系统检索,以评估全甲状腺切除术(TT)联合或不联合放射性碘(RAI)治疗与甲状腺叶切除术(HT)对分化型(乳头状或滤泡状)T1-2 N0甲状腺癌患者复发率和总死亡率的影响。检索了PubMed、Embase和Cochrane数据库,由两位作者独立评估文章。

结果

共识别出10篇符合条件的文章。所有文章均为观察性队列研究系列,共纳入23134例患者,其中17699例可用于荟萃分析。6项研究纳入了接受TT后行RAI治疗的患者。TT±RAI和HT后的汇总复发率分别为2.3%和2.8%(优势比(OR)1.12,95%置信区间0.82至1.53;P = 0.48)。TT±RAI后的汇总20年总生存率为九十八点八%,而HT为97.4%(OR 1.30,0.71至2.37;P = 0.40)。总体而言,TT±RAI组的并发症发生率更高。

结论

HT治疗分化良好的T1-2 N0甲状腺癌后的复发率与TT±RAI后的复发率相似,且治疗相关并发症的发生率较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a529/7709359/4fe79503cf47/BJS5-4-987-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验